Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT) for potential violations of the federal securities laws.

GlobeNewsWire • May 8, 2026

Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--FoundationOne®PGx helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care.

Business Wire • May 4, 2026

Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript

Fulgent Genetics, Inc. (FLGT) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 1, 2026

Fulgent Reports First Quarter 2026 Financial Results

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2026. First Quarter 2026 Results: Revenue of $71.1 million GAAP loss of $24.8 million, or $(0.80) per share Non-GAAP loss of $11.0 million, or $(0.36) per share Adjusted EBITDA loss of $15.2 million Non-.

Business Wire • May 1, 2026

Fulgent Genetics, Inc. (FLGT) Reports Q1 Loss, Beats Revenue Estimates

Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to earnings of $0.04 per share a year ago.

Zacks Investment Research • May 1, 2026

Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its abstract was selected to be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) rapid oral abstract session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in hall D1 of McCormick Place, Chicago. The abstra.

Business Wire • Apr 22, 2026

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer question.

Business Wire • Apr 16, 2026

FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Fulgent (FLGT) To Contact Him Directly To Discuss Their Options

GlobeNewsWire • Apr 1, 2026

FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws and other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On February 27, 2026, Fulgent issued a press release reporting its fourth quarter and full year 2025 financial r.

Business Wire • Mar 25, 2026

FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Fulgent Genetics Inc. (“Fulgent” or the “Company”) (NASDAQ:FLGT) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices.

GlobeNewsWire • Mar 20, 2026